PMA · Approved
ApprovedLIAISON QuantiFERON - TB Gold Plus, LIAISON Control QuantiFERON - TB Gold Plus and LIAISON QuantiFERON Software
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
DiaSorin, Inc. · NCD Test, Immunity, Cell Mediated, Mycobacterium Tuberculosis
Approved on Nov 26, 2019 through premarket approval, which rests on the device’s own clinical evidence after a 351-day review.
- Decided
- Nov 26, 2019
- Review
- 351 days
- Class
- Class III
- Product code
- NCD
- Recalls
- None
PMA approvals rest on their own clinical evidence and do not claim a predicate, so this family tree starts here.
P180047 has 42 supplements since 2020: changes to the approved device, its labelling or its manufacturing, each approved separately.
PMA supplements approved per year
View FIG. 1 as a table
| Year | Supplements approved |
|---|---|
| 2020 | 6 |
| 2021 | 5 |
| 2022 | 8 |
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 9 |
| 2026 | 5 |
Sources: FDA PMA database (decision fields and supplements), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in NCD? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
- Candidate predicates for a device like this, rankedin the report
- Recall history across each candidate’s familyin the report
Does it have a predicate?
PMA decisions do not claim a predicate device.
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
How does its category compare?
All NCD devicesNCD Test, Immunity, Cell Mediated, Mycobacterium Tuberculosis: FDA decisions, review times, recalls and adverse event reports over 20 years. 2019, this device’s year, is highlighted.
FDA decisions per year · NCD
10in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · NCD
Too few NCD 510(k)s in any year since 2007 to give a median.
Recalls per year · NCD
2in 2012
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · NCD
1in 2025
MAUDE reports naming product code NCD, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 2 | — | 0 | 0 |
| 2008 | 1 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 3 | — | 0 | 0 |
| 2011 | 3 | — | 0 | 0 |
| 2012 | 1 | — | 2 | 0 |
| 2013 | 0 | — | 0 | 8 |
| 2014 | 4 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 6 |
| 2016 | 3 | — | 0 | 10 |
| 2017 | 6 | — | 0 | 0 |
| 2018 | 5 | — | 0 | 0 |
| 2019 | 6 | — | 0 | 0 |
| 2020 | 6 | — | 0 | 1 |
| 2021 | 6 | — | 0 | 0 |
| 2022 | 8 | — | 0 | 0 |
| 2023 | 6 | — | 0 | 0 |
| 2024 | 6 | — | 0 | 2 |
| 2025 | 10 | — | 0 | 1 |
| 2026 | 7 | — | 0 | — |
https://510kreport.com/device/P180047 · printed Nov 5, 2026
Cite this page
510(k) Report. “P180047: LIAISON QuantiFERON - TB Gold Plus, LIAISON Control QuantiFERON - TB Gold Plus and LIAISON QuantiFERON Software.” Lineage record from FDA PMA data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/P180047
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Page last updated Nov 3, 2026